These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 22584072)

  • 21. Efficacy and safety of rivaroxaban thromboprophylaxis after arthroplasty of the hip or knee: retrospective cohort study.
    Loganathan V; Hua A; Patel S; Gibbons C; Vizcaychipi MP
    Ann R Coll Surg Engl; 2016 Sep; 98(7):507-15. PubMed ID: 27580310
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A RCT study of Rivaroxaban, low-molecular-weight heparin, and sequential medication regimens for the prevention of venous thrombosis after internal fixation of hip fracture.
    Tang Y; Wang K; Shi Z; Yang P; Dang X
    Biomed Pharmacother; 2017 Aug; 92():982-988. PubMed ID: 28605879
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rivaroxaban: new drug. After hip or knee replacement surgery: LMWH is safer.
    Prescrire Int; 2009 Aug; 18(102):151-3. PubMed ID: 19743567
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of anticoagulation with rivaroxaban in trauma and acute care surgery: Complications and reversal strategies as compared to warfarin therapy.
    Myers SP; Dadashzadeh ER; Cheung J; Alarcon L; Kutcher M; Brown JB; Neal MD
    J Trauma Acute Care Surg; 2017 Mar; 82(3):542-549. PubMed ID: 28045742
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement.
    Eriksson BI; Borris LC; Dahl OE; Haas S; Huisman MV; Kakkar AK; Muehlhofer E; Dierig C; Misselwitz F; Kälebo P;
    Circulation; 2006 Nov; 114(22):2374-81. PubMed ID: 17116766
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low-Molecular-Weight Heparin and the Relative Risk of Surgical Site Bleeding Complications: Results of a Systematic Review and Meta-Analysis of Randomized Controlled Trials of Venous Thromboprophylaxis in Patients After Total Joint Arthroplasty.
    Suen K; Westh RN; Churilov L; Hardidge AJ
    J Arthroplasty; 2017 Sep; 32(9):2911-2919.e6. PubMed ID: 28522244
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral direct factor Xa inhibitor versus enoxaparin for thromboprophylaxis after hip or knee arthroplasty: Systemic review, traditional meta-analysis, dose-response meta-analysis and network meta-analysis.
    Feng W; Wu K; Liu Z; Kong G; Deng Z; Chen S; Wu Y; Chen M; Liu S; Wang H
    Thromb Res; 2015 Dec; 136(6):1133-44. PubMed ID: 26498222
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of oral factor Xa inhibitor and low-molecular-weight heparin on surgical complications following total hip arthroplasty.
    Kim SM; Moon YW; Lim SJ; Kim DW; Park YS
    Thromb Haemost; 2016 Mar; 115(3):600-7. PubMed ID: 26790579
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Rivaroxaban versus standard of care in venous thromboembolism prevention following hip or knee arthroplasty in daily clinical practice (Spanish data from the international study XAMOS)].
    Granero J; Díaz de Rada P; Lozano LM; Martínez J; Herrera A;
    Rev Esp Cir Ortop Traumatol; 2016; 60(1):44-52. PubMed ID: 26194908
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials.
    Huisman MV; Quinlan DJ; Dahl OE; Schulman S
    Circ Cardiovasc Qual Outcomes; 2010 Nov; 3(6):652-60. PubMed ID: 20923996
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Phase IV Study of Thromboembolic and Bleeding Events Following Hip and Knee Arthroplasty Using Oral Factor Xa Inhibitor.
    Gomez D; Razmjou H; Donovan A; Bansal VB; Gollish JD; Murnaghan JJ
    J Arthroplasty; 2017 Mar; 32(3):958-964. PubMed ID: 27843040
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thrombocytopenia due to rivaroxaban: A rare adverse effect.
    Tığlıoğlu M; Akyol P; Sağlam B; Aras MR; Afacan Öztürk HB; Yıldız A; Albayrak M
    Transfus Apher Sci; 2020 Dec; 59(6):102883. PubMed ID: 32807650
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.
    Stevenson M; Scope A; Holmes M; Rees A; Kaltenthaler E
    Health Technol Assess; 2009 Oct; 13 Suppl 3():43-8. PubMed ID: 19846028
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aspirin compared to enoxaparin or rivaroxaban for thromboprophylaxis following hip and knee replacement.
    Ní Cheallaigh S; Fleming A; Dahly D; Kehoe E; O'Byrne JM; McGrath B; O'Connell C; Sahm LJ
    Int J Clin Pharm; 2020 Jun; 42(3):853-860. PubMed ID: 32328957
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of rivaroxaban use in patients with gynecologic malignancies at an academic medical center: A pilot study.
    Signorelli JR; Gandhi AS
    J Oncol Pharm Pract; 2019 Mar; 25(2):362-368. PubMed ID: 29157146
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgery.
    Turpie AG; Schmidt AC; Kreutz R; Lassen MR; Jamal W; Mantovani L; Haas S
    Vasc Health Risk Manag; 2012; 8():363-70. PubMed ID: 22701330
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic potential of rivaroxaban in the prevention of venous thromboembolism following hip and knee replacement surgery: a review of clinical trial data.
    Kwong LM
    Vasc Health Risk Manag; 2011; 7():461-6. PubMed ID: 21822393
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of switch-therapy modalities (enoxaparin to rivaroxaban/dabigatran) and enoxaparin monotherapy after hip and knee replacement.
    Özler T; Uluçay Ç; Önal A; Altıntaş F
    Acta Orthop Traumatol Turc; 2015; 49(3):255-9. PubMed ID: 26200403
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Responsible, Safe, and Effective Use of Antithrombotics and Anticoagulants in Patients Undergoing Interventional Techniques: American Society of Interventional Pain Physicians (ASIPP) Guidelines.
    Kaye AD; Manchikanti L; Novitch MB; Mungrue IN; Anwar M; Jones MR; Helander EM; Cornett EM; Eng MR; Grider JS; Harned ME; Benyamin RM; Swicegood JR; Simopoulos TT; Abdi S; Urman RD; Deer TR; Bakhit C; Sanapati M; Atluri S; Pasupuleti R; Soin A; Diwan S; Vallejo R; Candido KD; Knezevic NN; Beall D; Albers SL; Latchaw RE; Prabhakar H; Hirsch JA
    Pain Physician; 2019 Jan; 22(1S):S75-S128. PubMed ID: 30717501
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparing Length of Stay Between Patients Taking Rivaroxaban and Conventional Anticoagulants for Treatment of Venous Thromboembolism.
    Desai A; Desai A; Calixte R; Aparnath M; Hindenburg A; Salzman S; Mathew JP
    Lung; 2016 Aug; 194(4):605-11. PubMed ID: 27192990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.